|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM148943187 |
| 003 |
DE-627 |
| 005 |
20231223050657.0 |
| 007 |
tu |
| 008 |
231223s2004 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0497.xml
|
| 035 |
|
|
|a (DE-627)NLM148943187
|
| 035 |
|
|
|a (NLM)15207780
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Sun, J-B
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells
|
| 264 |
|
1 |
|c 2004
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.08.2004
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We investigated the development of CD8+ tumor-specific cytotoxic lymphocytes (CTL) and protection against tumor growth after vaccination with bone marrow-derived dendritic cells (DC) pulsed with a model protein ovalbumin conjugated to cholera toxin (OVA-CT) in B6 mice using E.G7 tumor cells expressing OVA(257-264) peptide (SIINFEKL) as target cells in vitro and in vivo. Vaccination with OVA-CT-pulsed DC concurrently induced strong CTL in vitro activity and anti-E.G7 tumor protection in vivo in WT, NK-depleted and CD4-deficient mice as well as in IL-12-/- and IFN-gamma-/- mice but not in CD8-deficient mice. Importantly, activation of CTL by OVA-CT-pulsed DC was dependent on CT-induced activation of adenylate cyclase and increased cAMP production by DC associated with increased expression of MHC class I and co-stimulatory molecules (CD80, CD86 and CD40). These results show that vaccination with DC pulsed with antigens (Ag) conjugated to CT induces a strong CTL response and suggest that conjugation of tumor Ag to CT for DC vaccination represents a promising approach for tumor vaccination and immunotherapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Adjuvants, Immunologic
|2 NLM
|
| 650 |
|
7 |
|a Antigens, Neoplasm
|2 NLM
|
| 650 |
|
7 |
|a Egg Proteins
|2 NLM
|
| 650 |
|
7 |
|a Immunotoxins
|2 NLM
|
| 650 |
|
7 |
|a OVA-8
|2 NLM
|
| 650 |
|
7 |
|a Peptide Fragments
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 650 |
|
7 |
|a Ovalbumin
|2 NLM
|
| 650 |
|
7 |
|a 9006-59-1
|2 NLM
|
| 650 |
|
7 |
|a Cholera Toxin
|2 NLM
|
| 650 |
|
7 |
|a 9012-63-9
|2 NLM
|
| 650 |
|
7 |
|a Cyclic AMP
|2 NLM
|
| 650 |
|
7 |
|a E0399OZS9N
|2 NLM
|
| 700 |
1 |
|
|a Eriksson, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, B-L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lindblad, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Azem, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Holmgren, J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 112(2004), 1 vom: 16. Juli, Seite 35-44
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:112
|g year:2004
|g number:1
|g day:16
|g month:07
|g pages:35-44
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 112
|j 2004
|e 1
|b 16
|c 07
|h 35-44
|